Underestimation of the valvulopathy effect of fenfluramine [5] (multiple letters)

Journal of the American College of Cardiology

Volumn 36, Issue 4, 2000, Pages 1434-1435

  Moyé, Lemuel A ^a   Annegers, A Fred ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENFLURAMINE;

ADULT; AGE DISTRIBUTION; AGED; AORTA VALVE REGURGITATION; DRUG SAFETY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MITRAL VALVE REGURGITATION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0033810014     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00835-4     Document Type: Letter

References (4)

1. A.J. Burger H.B. Sherman M.J. Charlamb Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months J Am Coll Cardiol 34 1999 1153 1158
2. N.B. Schiller Fen/phen and valvular heart disease if it sounds too bad to be true, perhaps it isn’t J Am Coll Cardiol 34 1999 1159 1161
3. J.P. Singh J.C. Evans D. Levy Prevalence and clinical determinants of mitral, tricuspid and aortic regurgitation the Framingham study (abstr) Circulation 96 1997 I541
4. J.P. Singh J.C. Evans D. Levy Prevalence and clinical determinants of mitral, tricuspid and aortic regurgitation (the Framingham study) Am J Cardiol 83 1999 897 902